Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oncology ABCs (part 2) Webinar – Vaccines: Niche no longer

Oncology ABCs (part 2) Webinar – Vaccines: Niche no longer

As a follow-on to Oncology ABCs (part 2) – Vaccines: Niche no longer, we spoke to two seasoned oncology experts to better understand the innovative technologies, recent trends and momentum in combination therapies. The most notable and recent catalysts are expected to continue to fuel advances and include heightened immunotherapy awareness, momentum in combination therapies (extending survival) and a drive for personalised medicine. We expect these recent trends and overall wider acceptance of complex vaccines to reinvigorate deal activity which targets companies with the most robust and innovative technologies.

Jens Bjørheim, Chief Medical Officer of Ultimovacs
Jeroen Rovers, Chief Medical Officer of Mendus (previously Immunicum)
Soo Romanoff, Managing Director – Healthcare, Head of Content, Edison Group

< Previous
Next >

You may also be interested in these:

Healthcare

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Healthcare

Volition webinar: Nu.Q NETs data insights

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free